Professional background
Professor Faiz Mumtaz over the course of the last 21 years, has dedicated himself to advancing the understanding and treatment of renal cancer, particularly through laparoscopic and robotic kidney cancer surgery. He has established a high-volume renal cancer surgical practice at the prestigious Royal Free Hospital, and in addition to his clinical practice, Professor Mumtaz has made significant strides in academia and education. He holds the esteemed position of Professor of Urology at UCL. As the Director of the renal cancer fellowship program at the Royal Free London NHS Foundation Trust, he oversees the training and development of fellows specializing in robotic kidney cancer surgery.
Professor Mumtaz plays a pivotal role in the academic community as an examiner and supervisor for postgraduate research degrees (MD & PhDs) at UCL and several other renowned universities nationally. His dedication to research is exemplified by the establishment of a dedicated Meena Raja Kidney Cancer Research Laboratory at the Institute of Immunology and Transplantation within the newly developed Pears Building at the Royal Free Hospital. He has pioneered the development of a ground-breaking 3D Artificial Intelligence imaging program for surgical planning of complex kidney tumours. This innovative technology has enabled precise and personalized interventions, allowing for robotic and open partial nephrectomy procedures that preserve the maximum functionality of the remaining kidney. Recognizing the potential impact of this program, Professor Mumtaz has introduced this to numerous high-volume kidney cancer centres across the country, leading to a grant from the prestigious National Institute of Health Research.
As a testament to his commitment to research and his passion for improving patient outcomes, Professor Mumtaz chairs the Meena Raja Kidney Cancer Research Foundation. This foundation actively engages in fundraising initiatives to support innovative research projects aimed at advancing our understanding of renal cancer and developing more effective treatment strategies. Additionally, Professor Mumtaz supervises several PhD students who are conducting research in the field of renal cancer.
He is a member the British Association of Urological Surgeons and the Royal College of Surgeons (England). In recognition of his expertise and leadership, he serves as the National Lead of Societe' Internationale Urologie, representing the British Association of Urological Surgeons.
Professor Mumtaz's impact extends beyond his clinical practice, research, and leadership roles. He is a prolific author with well over 130 published articles and a textbook on Urological Emergencies. Furthermore, he is a sought-after speaker at both national and international urological conferences, where he delivers invited lectures and organizes workshops on laparoscopic and robotic renal cancer surgery.
In summary, Professor Faiz Mumtaz's has had a remarkable career in urology encompassing pioneering advancements in renal cancer surgery, establishment of a renowned research laboratory, impactful contributions to academia and education, and influential leadership roles within esteemed urological organizations. His unwavering dedication to improving patient outcomes and advancing the field of urology has solidified his status as a true pioneer and a respected authority in renal cancer surgery and research.
Specialties
Research interests
The role of vasoactive mediators in pathophysiology of bladder and erectile dysfunction and cancers of the prostate and kidney.
Leading the first clinical research program in the UK on the utility of 3D imaging for surgical planning of complex kidney cancer surgery in collaboration with Innersights Labs Ltd (as the co-founder) and the Translational Research Group at UCL/KCL. A novel Artificial Intelligence (AI) guided software was developed to create virtual 3D interactive kidney tumour models from routine preoperative 2D CT scans to provide precise relationship of the tumour to vital renal anatomical/vascular structures which has been integrated into clinical practice for surgical planning and patients’ education.
Principal Investigator/Co-investigator for novel multicentre trials to assess the role of novel neoadjuvant immunotherapies in the surgical management of advanced renal cancers.
Created a “Kidney Cancer Research laboratory and Research Foundation” through public engagement at the Institute of Immunology and Transplantation (IIT) at RFH/UCL. This new laboratory has facilitated disease-focused, cutting-edge translational research program that will enhance our understanding of the human immune system in kidney cancer and provide the key to implementing novel interventions to improve diagnosis and treatment for patients.
The research plan within this facility over the next 5 years is to explore prognostic/therapeutic markers in early and advanced kidney cancer.
Languages spoken
Urdu
Publications
Aquilina J, Neves JB, El-Sheikh S, Tran-Dang MA, Walkden M, Barod R, Patki P, Mumtaz F, Bex A, Tran MGB. Epitheliod Angiomyolipomas of the kidney: Rare tumours associated with poor prognosis. Urology. 2023 Apr 6:S0090-4295(23).
Warren H, Boydell AR, Reza A, Pencharz D, Holman BF, El-Sheikh S, Wildgoose WH, Barod R, Patki P, Mumtaz F, Bex A, Wagner T, Tran MGB. Use of 99m Tc-sestamibi SPECT/CT for indeterminate renal tumours: a pilot diagnostic accuracy study. BJU Int. 2022 Dec;130(6):748-750.
Stewart GD, Welsh SJ, Ursprung S, Gallagher FA, Jones JO, Shields J, Smith CG, Mitchell TJ, Warren AY, Bex A, Boleti E, Carruthers J, Eisen T, Fife K, Hamid A, Laird A, Leung S, Malik J, Mendichovszky IA, Mumtaz F, Oades G, Priest AN, Riddick ACP, Venugopal B, Welsh M, Riddle K, Hopcroft LEM; NAXIVA Trial Group; Jones RJ. A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA) Br J Cancer. 2022 Oct;127(6):1051-1060.
Miller J, Campain N, Boydell AR, Warren H, Vito I, Neves J, Mumtaz F, Bex A, El-Shiekh S, Wagner T, Tran MGB. 'Case of the Month' from the Specialist Centre for Kidney Cancer, Royal Free London Hospital, UK: 99m Tc-sestamibi SPECT-CT to differentiate renal cell carcinoma from benign oncocytoma. BJU Int. 2022 Jan;129(1):28-31
Morka N, Berger L, Hyde E, Mumtaz F, Barod R, Patki P, Graafland N, Hendricksen K, Tran M, Bex A. (2021).
Interactive virtual 3-D image reconstruction to assist renal surgery in patients with fusion anomalies of the kidney. Journal of Clinical Urology, https://doi.org/10.1177/20514158211068310.
Graafland NM, Szabados B, Tanabalan C, Kuusk T, Mumtaz F, Barod R, Nicol D, Boleti E, Powles T, Haanen JB, Bex A. (2021). Surgical safety of deferred cytoreductive nephrectomy following pre-treatment with immune checkpoint inhibitor based dual combination therapy. Eur Urol Oncol. 2022 Jun;5(3):373-374.
Berger L, Gulamhusein A, Hyde E, Gibb M, Kuusk T, Neves J, Silva P, Marchetti M, Barod R, Tran M, Patki P, Bex A, Ourselin S, Dasgupta P, Mumtaz F. (2021). Clinical experience of using virtual 3D modelling for pre and intraoperative guidance during robotic-assisted partial nephrectomy. Journal of Clinical Urology, https://doi.org/10.1177/20514158211000204
Kuusk T, Cullen D, Neves JB, Campain N, Barod R, Boleti E, El-Sheikh S, Grant L, Kelly J, Marchetti M, Mumtaz F, Patki P, Ramachandran N, Silva P, Tran-Dang M, Walkden M, Tran M, Powles T, Bex A. (2021). Impact of the first surge of the COVID-19 pandemic on a tertiary referral centre for kidney cancer. BJU Int. 2021 Dec;128(6):752-758.
Neves JB, Vanaclocha SL, Abu-Ghanem Y, Marchetti M, Tran-Dang M-A, El-Sheikh S, Barod R, Beisland C, Capitanio U, Cullen D, Klatte T, Ljungberg B, Mumtaz F, Patki P, Stewart GD, Dabestani S, Tran MGB, Bex A, RECUR consortium (2021). Pattern, timing, and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma. World J Urol. 2021 Oct;39(10):3823-3831.
Fernandez-Pello S, Verma N, Kuusk T, Berezowska A, Mumtaz F, Patki P, Tran M, Barod R, Bex A (2021). Perioperative impact of body mass index on upper urinary tract and renal robot-assisted surgery: a single high-volume centre experience. J Robot Surg. 2022 Jun;16(3):611-619.
Kuusk T, Abu-Ghanem Y, Mumtaz F, Powles T, Bex A (2021). Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy. Current Opinion in Urology, 31 (3), 262-269.
Aquilina J, Neves J, Berger L, Mumtaz F, Banga N, Tran M (2020). Images in Clinical Urology: Complex open pyeloplasty in a pelvic kidney. Urology, 141, pp. e47-e48.
Gulamhusein A, Silva P, Cullen D, Tran M, Mumtaz F, Patki P, Barod R, Bex A (2020). Safety and feasibility of early single-dose mitomycin C bladder instillation after robot-assisted radical nephroureterectomy. British Journal of Urology International, 126 (6), pp. 739-744.
Parker JTS, Raman A, Mumtaz F. (2019). A rare case of renal angiomyolipoma extending into the renal vein. Journal of Clinical Urology, 12 (1), 72-74.
Hyde ER, Berger LU, Ramachandran N, Hughes-Hallett A, Pavithran NP, Tran MGB, Ourselin S, Bex A, Mumtaz FH. (2019). Interactive virtual 3D models of renal cancer patient anatomies alter partial nephrectomy surgical planning decisions and increase surgeon confidence compared to volume-rendered images. International Journal of Computer Assisted Radiological Surgery, 14 (4), pp. 723-732.
Neves J, Cullen D, Lee G, Walkden M, Bandula S, Patki P, Barod R, Mumtaz F, Aitchison M, Pizzo E, Ranieri V, Williams N, Wildgoose W, Guruswamy K, Emberton M, Bex A, Tran M. (2019). Protocol for a feasibility study of a cohort embedded randomised controlled trial comparing NEphron Sparing Treatment (NEST) for small renal masses. BMJ Open, 9 (6).
Berger L, Mumtaz F. (2019). Will three-dimensional models change the way nephrometric scoring is carried out?. British Journal of Urology International, 124 (6), 898-899.
Neves JB, Withington J, Fowler S, Patki P, Barod R, Mumtaz F, O'Brien T, Aitchison M, Bex A, Tran MG, British Association of Urological Surgeons (BAUS). (2018). Contemporary surgical management of renal oncocytoma: a nation's outcome. British Journal of Urology international, 121 (6), pp. 893-899.
Tanabalan C, Raman A, Mumtaz F. (2018). Robot-assisted partial nephrectomy: How to minimise renal ischaemia. Arab Journal of Urology, 16 (3), 350-356.
Raman A, Kuusk T, Hyde ER, Berger LU, Bex A, Mumtaz F (2018). Robotic-assisted Laparoscopic Partial Nephrectomy in a Horseshoe Kidney. A Case Report and Review of the Literature. Urology, 114 E3-E5.
Ertemi H, Khetrapal P, Pavithran NM, Mumtaz F (2017). Optimising renal cancer patients for nephron-sparing surgery: a review of pre-operative considerations and peri-operative techniques for partial nephrectomy. Urologia, 84 (1), 20-27.
Chan K, Al-Roubaie J, El Sheikh S, Mumtaz F (2016). Hepatitis and Solitary Left Renal Mass: Renal Hepatocellular Carcinoma. Urology, 96 114-115.
Tran MGB, Tadtayev S, Palmer T, Evans A, Mumtaz F. (2016). Sign of the times: be careful what you say in the operating room. Lancet, 387 (10018), P 536.
Ertemi H, Mumtaz FH, Howie AJ, Mikhailidis DP, Thompson CS. (2011). Effect of Angiotensin II and its Receptor Antagonists on Human Corpus Cavernous Contractility and Oxidative Stress: Modulation of Nitric Oxide Mediated Relaxation. Journal of Urology, 185 (6), 2414-2420.
Kommu SS, Illahi I, Mumtaz F. (2007). Patterns of urethral injury and immediate management. Current Opinion in Urology, 17 (6), 383-389.
Mumtaz FH, Kommu SS, Siddiqui E, Le Roux PJ, Hellawell G, Hemal AK (2006). Minimally invasive treatment of ureteropelvic junction obstruction: Optimizing outcomes with concomitant cost reduction. Journal of Endourology, 20 (9), 663-668.
Siddiqui EJ, Shabbir MA, Mikhailidis DP, Mumtaz FH, Thompson CS (2006). The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation. British Journal of Urology International, 97 (3), 634-639.
Siddiqui EJ, Shabbir M, Mikhailidis DP, Thompson CS, Mumtaz FH (2006). The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation. Journal of Urology, 176 (4 Pt 1), 1648-1653.
Siddiqui EJ, Thompson CS, Mikhailidis DP, Mumtaz FH. (2005). The role of serotonin in tumour growth (review). Oncology Reports, 14 (6), 1593-1597.
Mumtaz FH, Chew H, Gelister JS. (2002). Lower limb compartment syndrome associated with the lithotomy position: concepts and perspectives for the urologist. British Journal of Urology International, 90 (8), 792-799.
Mumtaz FH, Dashwood MR, Thompson CS, Khan MA, Naylor AM, Mikhailidis DP, Morgan RJ. (2001). Autoradiographic localisation and contractile properties of prostatic endothelin receptors in patients with bladder outlet obstruction. European Urology, 39 (1), 48-56.
Thompson CS, Mumtaz FH, Khan MA, Wallis RM, Mikhailidis DP, Morgan RJ, Angelini GD, Jeremy JY. (2001). The effect of sildenafil on corpus cavernosal smooth muscle relaxation and cyclic GMP formation in the diabetic rabbit. European Journal of Pharmacology, 425 (1), 57-64.
Mumtaz FH, Khan MA, Thompson CS, Morgan RJ, Mikhailidis DP. (2000). Nitric oxide in the lower urinary tract: physiological and pathological implications. British Journal of Urology International, 85 (5), 567-578.
Mumtaz FH, Sullivan ME, Thompson CS, Dashwood MR, Naseem KM, Bruckdorfer KR, Mikhailidis DP, Morgan RJ. (1999). Alterations in the nitric oxide synthase binding sites and non-adrenergic, non-cholinergic mediated smooth muscle relaxation in the diabetic rabbit bladder outlet: possible relevance to the pathogenesis of diabetic cystopathy 3. Journal of Urology, 162 (2), 558-566.
Mumtaz FH, Khan MA, Sullivan ME, Thompson CS, Mikhailidis DP, Morgan RJ, Dashwood MR. (1999). Potential role of endothelin and nitric oxide in physiology and pathophysiology of the lower urinary tract. Endothelium - New York, 7 (1), 1-9.
Mumtaz FH, Thompson CS, Dashwood MR, Mikhailidis DP, Fowlis GA, Morgan RJ. (1997). Endothelin receptor localisation and contractile studies in human prostatic tissue: relevance to benign prostatic hyperplasia. British Journal of Urology, 80 (SUPPL. 2), 182-183.